Vifor Pharma Group 보도자료

2021년 10월 27일 17:40

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placeb...

2021년 10월 12일 17:40

Vifor Pharma announces changes to its Executive Committee

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced changes to its Executive Committee as current members Lee Heeson, President International, and Gregory Oakes, President North America, have decided to l...

2021년 9월 28일 14:30

VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment o...

2021년 9월 17일 11:40

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of...

2021년 8월 31일 17:13

Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines

Regulatory News: Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure for two of ...

2021년 8월 24일 14:50

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News: Vifor Pharma and Cara Therapeutics (Nasdaq:CARA) today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with...

2021년 8월 5일 16:30

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance[1]

Regulatory News: Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient access as COVID-19 restrictions eased in key markets...

2021년 6월 25일 13:40

Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma

Regulatory News: Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharm...

2021년 6월 25일 11:10

Vifor Pharma to revise DIAMOND study, readout expected in H2 2021

Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in potassium management in high-risk heart failure pati...

2021년 4월 30일 14:28

VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21) compared to sevelamer carbonate in lowering and main...

2021년 4월 29일 16:16

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion’s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CS...

2021년 4월 28일 17:05

First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment

Regulatory News: Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical stud...

2021년 3월 30일 19:55

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for difelikefa...

2021년 3월 29일 13:50

Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors

Regulatory News: Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021. Åsa Riisberg, a Swedish citizen, was formerly Partner and member of t...

2021년 3월 8일 15:37

Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solu...

2021년 3월 3일 18:45

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth[1]

Regulatory News: Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much stronger Swiss franc against the US dollar. FINANCI...

2021년 2월 2일 19:10

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Regulatory News: Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021. Jacques Theurillat, Chairman of Vifor Pharma, commented: “We ar...

2020년 11월 26일 17:10

Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality

Regulatory News: Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron deficiency anemia[1] - with the support of international org...

2020년 11월 19일 17:47

VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia in the People’s Republic of China. Under the agreem...

2020년 11월 16일 09:22

Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency

Regulatory News: Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results were published in the peer-reviewed medical journal...

2020년 11월 9일 15:39

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Regulatory News: Vifor Pharma and Angion Biomedica Corp. (Angion) announced the signing of a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed graft function (DGF) and cardiac surgery-associate...

2020년 11월 3일 16:09

VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorization Application (MAA) for avacopan for the treatme...

2020년 10월 21일 11:48

Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“i.v. Korsuva”) for the treatment of chronic ki...

2020년 9월 25일 17:43

Vifor Pharma announces outcome of AFFIRM-AHF topline data

Regulatory News: Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject® (intravenous ferric carboxymaltose) on heart failure hospitalizations and cardiovascular mortality in iron-deficient patients ...

2020년 9월 18일 16:02

Vifor Pharma Group Announces Successful Sale of OM Pharma

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: · A purchase consideration of MCHF 435 for 100% of...

Vifor Pharma Group 보도자료

Vifor Pharma Group 보도자료

Vifor Pharma Group

회사 보도자료 구독